2019 国际共识声明:远端胆管狭窄的内镜管理

2019-12-04 肝胆外科专家组(统称) J Gastroenterol Hepatol. 2019 Dec 4.

远端胆管狭窄(DBS)常见,可由恶性或良性病变引起。内镜治疗在DBS的管理中起了非常重要的作用。本文主要针对远端胆管狭窄的内镜管理提出了19条共识声明,主要涉及诊断,内镜下引流,良性以及恶性胆管狭窄的管理以及复发性胆道梗阻等并发症的管理。

中文标题:

2019 国际共识声明:远端胆管狭窄的内镜管理

英文标题:

International consensus statements for endoscopic management of distal biliary stricture

发布日期:

2019-12-04

简要介绍:

远端胆管狭窄(DBS)常见,可由恶性或良性病变引起。内镜治疗在DBS的管理中起了非常重要的作用。本文主要针对远端胆管狭窄的内镜管理提出了19条共识声明,主要涉及诊断,内镜下引流,良性以及恶性胆管狭窄的管理以及复发性胆道梗阻等并发症的管理。

 

拓展指南:胆管相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 国际共识声明:远端胆管狭窄的内镜管理)] GetToolGuiderByIdResponse(projectId=1, id=93af91c0018a1321, title=2019 国际共识声明:远端胆管狭窄的内镜管理, enTitle=International consensus statements for endoscopic management of distal biliary stricture, guiderFrom=J Gastroenterol Hepatol. 2019 Dec 4., authorId=null, author=, summary=远端胆管狭窄(DBS)常见,可由恶性或良性病变引起。内镜治疗在DBS的管理中起了非常重要的作用。本文主要针对远端胆管狭窄的内镜管理提出了19条共识声明,主要涉及诊断,内镜下引流,良性以及恶性胆管狭窄的管理以及复发性胆道梗阻等并发症的管理。 , cover=, journalId=null, articlesId=null, associationId=701, associationName=肝胆外科专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Dec 04 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>远端胆管狭窄(DBS)常见,可由恶性或良性病变引起。内镜治疗在DBS的管理中起了非常重要的作用。本文主要针对远端胆管狭窄的内镜管理提出了19条共识声明,主要涉及诊断,内镜下引流,良性以及恶性胆管狭窄的管理以及复发性胆道梗阻等并发症的管理。</P> <P> </P>拓展指南:<strong>与<font color=red>胆管</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=bf4d71c00182668c" title="肝胆管结石三维可视化精准诊治专家共识(2019版)" target=_blank>肝胆管结石三维可视化精准诊治专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=519fc1c001e995bb" title="腹腔镜肝门部胆管癌根治性切除操作流程专家建议" target=_blank>腹腔镜肝门部胆管癌根治性切除操作流程专家建议</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=21d7d1c001e8a75b" title="胆道镜在肝胆管结石病诊断与治疗中的应用专家共识(2019版)" target=_blank>胆道镜在肝胆管结石病诊断与治疗中的应用专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a48611c001e770b6" title="儿童胰胆管合流异常临床实践专家共识" target=_blank>儿童胰胆管合流异常临床实践专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c62b71c001e67863" title="2019 ASCO临床实践指南:已切除胆管癌的辅助治疗" target=_blank>2019 ASCO临床实践指南:已切除胆管癌的辅助治疗</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E8%83%86%E7%AE%A1" target=_blank>有关胆管更多指南</a></ul>, tagList=[TagDto(tagId=98145, tagName=远端胆管狭窄), TagDto(tagId=56089, tagName=内镜管理)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3342, appHits=86, showAppHits=0, pcHits=1991, showPcHits=2012, likes=60, shares=4, comments=3, approvalStatus=1, publishedTime=Tue Dec 24 20:44:36 CST 2019, publishedTimeString=2019-12-04, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Dec 24 20:44:36 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 04:45:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 国际共识声明:远端胆管狭窄的内镜管理)])
2019 国际共识声明:远端胆管狭窄的内镜管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1050068, encodeId=c92710500680f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383c3846239, createdName=13763a4cm02暂无昵称, createdTime=Mon Sep 13 22:01:15 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804501, encodeId=219880450111, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Sat Jul 25 11:49:50 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803404, encodeId=ff058034040d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:43:28 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2021-09-13 13763a4cm02暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1050068, encodeId=c92710500680f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383c3846239, createdName=13763a4cm02暂无昵称, createdTime=Mon Sep 13 22:01:15 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804501, encodeId=219880450111, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Sat Jul 25 11:49:50 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803404, encodeId=ff058034040d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:43:28 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-25 a6806376

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1050068, encodeId=c92710500680f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383c3846239, createdName=13763a4cm02暂无昵称, createdTime=Mon Sep 13 22:01:15 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804501, encodeId=219880450111, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Sat Jul 25 11:49:50 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803404, encodeId=ff058034040d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:43:28 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 海明明

    很好

    0